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Availability of brands of six essential medicines 
in 124 pharmacies in Maharashtra
Background The aim of this study is to assess the availability and ra-
tional use of six essential medicines in private retail outlets in Maha-
rashtra state. The study focuses on the range of brands for each med-
icine, and the availability of these brands in the pharmacies. The 
medicines were chosen because they are included in the World Health 
Organization’s (WHO) essential medicines list (EML), the Indian na-
tional and Maharashtra state medicines list, and are all included in ex-
isting Indian public health initiatives and national disease control pro-
grammes.
Methods Data was gathered on the availability of the medicines and 
the range and frequency of brands in 124 private retail pharmacies be-
tween January and May 2012. As there is currently no centralised da-
tabase in India of available pharmaceutical brands, we collected data 
on the range of products of the 6 essential medicines available in the 
Indian market by consulting three open access Indian pharmaceutical 
databases, CIMS India, Medindia, and Medguide, and the commercial 
database, Pharmatrac; we compared this data with the results of the 
survey. The six essential medicines used in this study are: artemisinin 
(malaria), lamivudine (HIV/AIDS), rifampicin (tuberculosis control), 
oxytocin (reproductive health), fluoxetine (mental health) and met-
formin (diabetes).
Results The study found that for each of the selected medicines there 
were multiple approved products listed in Indian databases, 2186 in 
total. The Pharmatrac database lists only 1359 brands of the selected 
medicines; 978 (72%) of these had zero sales in 2011-2012. Our sur-
vey found very low availability of the brands: 17% Pharmatrac mar-
keted brands (163/978) and 12% of all Pharmatrac brands (163/1359) 
were available. Metformin was the only medicine with high availabil-
ity in the study pharmacies at 91%, Rifampacin was the second highest 
at 64.5%; the other four medicines were available in less than half the 
pharmacies. A small number of brands were dominating the market.
Conclusion the survey shows that market competition has generated 
a large number of brands of the six study medicines but this has not 
translated into sufficient availability of these medicines in the study 
pharmacies. The data calls for a review of available brands, taking into 
consideration levels of sale and grounds for approval, and the setting 
up of a centralised database of registered pharmaceutical products.
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Essential medicines are defined by WHO as medicines which “satisfy the priority health care needs of the 
population”, they are, “selected with due regard to public health relevance, evidence on efficacy and safe-
ty, and comparative cost-effectiveness” [1]. The WHO published its first model list of essential medicine 
in 1977 (WHO EML) with the purpose of helping governments in low resource settings prioritise their 
spending on pharmaceuticals [1]. Given that an estimated 70% of pharmaceuticals on the global market 
are nonessential or duplicative, the aim of a limited list of essential medicines is to enable rational use, 
lower costs and improve access [2].
Health is a fundamental human right and access to essential medicines is a vital component of a function-
ing health system. Despite a wave of international initiatives to achieve universal access to safe and effec-
tive medicine, enshrined most recently in the Sustainable Development Goal 3.8, it is estimated that at 
least a third of the global population lacks access to medicines [3]. A recent United Nations report states 
that essential medicines are available in only 51.8% of public and 68.5% of private health facilities in low 
and middle income countries [4]. With low availability in the public health sector, patients must turn to 
the private sector where the prices of generic medicines are 2 to 3.5 times higher than international ref-
erence prices [3].
The WHO EML has a strong influence on the medicine policy of many countries. When the list was first 
published it contained 186 medicines, since that time the number has steadily increased; the list current-
ly contains 374 medicines, and 156 WHO member states have now adopted a medicine list [3]. India 
established its first National Essential Medicine List (NLEM) in 1996. The list was revised in 2003, 2011 
and most recently in 2015 [5]. The 2015 NLEM contains 376 medicines that meet the twin criteria of 
Indian disease prevalence and cost-effectiveness. Medicines in the NLEM are categorised for their essen-
tiality at Primary (P), Secondary (S) and Tertiary levels (T). The NEML is used as the basis for each Indi-
an state to form its own EML by adding or deleting selected medicines.
Health services in the public sector are provided free of charge and essential medicines listed on the NLEM 
should be available in public sector outlets but numerous studies have shown inadequate availability [6-
8], causing many patients to turn to the private sector. Part of the problem is government funding; World 
Bank data for 2011 show India’s public health expenditure at 1.2% of GDP, which is amongst the lowest 
in the world [9]. At the time of independence, private health sector utilisation was only 5%-10% [10]; 
today out-of-pocket expenditure on private health accounts for 80% of India’s total health expenditure 
[11]. Patients lose out in that prices of essential generic medicines in the private sector can be 2 to 3.5 
times higher than international reference prices [3].
A number of studies have been done on the prices and availability of medicines in India. Four studies 
used a methodology developed by WHO and Health Action International [12] to measure prices of med-
icines in low and middle income countries [13-16]. Each of these four studies evaluated the price and 
availability of medicines in both private and public sector facilities. As patients do not pay for medicines 
in public facilities, in this sector the studies collected data on procurement prices. All four of the studies 
showed that in the public sector, although procurement prices were low, availability was poor, while in 
the private sector, generic drugs were available but at a high price compared with the international refer-
ence price. A study of the availability of 27 essential medicines in six Indian states in public sector outlets 
found low median availability of 0%-30% [6]. A study in Maharashtra State of the availability of 10 es-
sential medicines in 36 primary health centres in 12 districts found insufficient stock of five essential 
medicines in 75% of the centres and no availability in 13% [17].
The inadequate availability of essential medicines in public health outlets stands in stark contrast to In-
dia’s status as a major producer and exporter of generic medicines. There are presently more than 10 500 
pharmaceutical manufacturing units in India [18]. Indian companies produce around 60 000 generic 
drugs and over 400 bulk drugs used in formulations [19]. The industry is ranked third globally in terms 
of volume and 14th in terms of value, and is growing at 16% per annum. India currently exports off-pat-
ent generic drugs to more than 200 countries, for this reason it is often dubbed “the pharmacy of the 
world” [20]. In theory, competition within India’s vast market for generic drugs should ensure that essen-
tial medicines are available in private retail outlets at a price people can afford. The aim of this study is to 
assess the effectiveness of market competition in contributing to the availability of six essential medicines 
in private retail outlets in Maharashtra state.
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METHODS
Study medicines
The present study forms part of an EU-FP7 research project on Accessing Medicine in Africa and South 
Asia. It focuses on the availability in private retail pharmacies in Maharashtra state, India, of six essential 
medicines. In India medicines are generally marketed and prescribed by brand name, not generic name. 
For this reason it was first necessary to assess the range of products within the pharmacies with specific 
trade names or brand names for each of the six medicines. The range of products available in the phar-
macies for each of the medicines was then compared with available data on the full range of brands avail-
able for each medicine in India; this data was obtained from three open access databases (CIMS India, 
Medindia, and Medguide) and one commercial database (Pharmatrac). We included data on the medi-
cines in both single drug formulations (SDF) and fixed dose combinations (FDC).
One of the reasons for choosing Maharashtra as the focus of this study is there is national disease control 
programmes in operation within the state related to the conditions associated with the six selected medicines 
[21,22]. Each of the six essential medicines which are the focus of this study are included in the WHO EML, 
the Indian NLEM and the Maharashtra state EML. Artesunate (P, S, T), a water soluble derivative of artemis-
inin, is listed in the NLEM for the treatment of malaria. India has a high prevalence of malaria with around 
2 million reported cases and 1000 annual deaths [23]. Lamivudine (S,T) is included in the section for an-
tiretroviral medicines for the treatment of HIV/AIDS, in a number of fixed dose combinations. The single 
drug formulation of lamivudine was deleted from the list in 2015, after this study. According to the the UN-
AIDS Gap Report [24] India has the third largest HIV epidemic with 2.1 million people living with the ill-
ness. Rifampicin (P,S,T), is listed in the NLEM for the treatment of both Tuberculosis and Leprosy. India has 
the highest levels of tuberculosis (TB) infection in the world. In 2013, India’s 2.1 million TB cases made up 
almost a quarter of the 9 million global incidence [25]. India also has the highest prevalence of Leprosy with 
134 752 new case reported in 2012 [26]. Oxytocin (S,T) is listed in the NEML for reproductive health. It is 
the internationally established first line drug used for active management of third stage labour. Although the 
maternal mortality ratio has been progressively declining in India, the estimated figure of 174 for 2015 re-
mains high with 45 000 maternal deaths that year [27]. Metformin (P,S,T) is listed in the NELM for diabetes. 
The number of people diagnosed with diabetes in India is increasing; there are 69.2 million people with the 
disease in the country which is the second highest after China’s 109.6 million [28]. Fluoxetine (P,S,T) is in-
cluded in the NLEM for the treatment of depression. A recent systematic review of the epidemiology of psy-
chiatric disorders in India estimates 20% of the adult population in India to be affected by some form of 
psychiatric disorder [23]. A study giving an overview of Indian research on depression notes studies vary in 
their estimates on prevalence in India from 1.7 to 74 per thousand population [29].
Setting
A further reason why we chose Maharashtra as the location for this research is it has the largest number 
of manufacturing plants of all Indian states, contributing to 38% of the country’s medicine exports [30]. 
It also has the largest number of sales units, which the Maharashtra Food and Drug Administration esti-
mates at 80 000 [31]. We determined availability of the medicines in four districts representing each geo-
graphical zone of the state: Dhule in the north, Sangli in the south, Nagpur in the east and Mumbai city 
district in the west (Figure 1). These districts were all classed by the Indian government as category A 
for HIV/AIDS, meaning that more than 1% of women who had been screened at antenatal clinics in the 
previous three years had the infection. The districts also have high rates of TB and Malaria. Table 1 gives 
the TB rate for each district and the percentage of Plasmodium falciparum (PF) malaria, the form treated 
by artemisinin based combination therapy. Retail pharmacies were purposively sampled based on their 
proximity to primary, secondary and tertiary public health facilities in urban and rural areas. 30 retail 
pharmacies were selected from Nagpur, 30 from Mumbai, 33 from Dhule and 31 from Sangli districts; 
similar numbers were selected from urban and rural areas, with the exception of Mumbai which is en-
tirely urban. In the rural areas, from randomly selected tuberculin units, we purposively selected one sub 
district hospital, one rural hospital and one primary health centre. In the survey, we chose two retail phar-
macies located near each of these health facilities. In the urban areas, from randomly selected tuberculin 
units, we purposively selected one district level hospital, one corporation hospital and one health post. 
We chose two retail pharmacies located near each of these health facilities. Data was gathered in the local 
language on the availability of the selected medicines from pharmacists working in the 124 pharmacies 
in four districts during January to May 2012.
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Figure 1. The four study districts in Maharashtra, India.
Table 1. District pharmacies and disease profiles for 2009-10
Districts
All AllopAthic phArmAcies 
(public AnD privAte) 
registereD unDer stAte 
regulAtions
privAte retAil phArmAcies 
unDer Druggists AnD chemists 
AssociAtion (intervieweD)
populAtion (in 
millions) 2011 
census
tb rAte mAlAriA pF 
percentAge
Mumbai City 
District
Not available
Urban 5000
3.09 217/100 000 21.0
Interviewed 30
Dhule 2094
Total 700
2.05 140/100 000 31.0
Urban 280
Rural 420
Interviewed 33
Nagpur 4039
Total 3000
4.65 145/10 000 34.0
Urban 500
Rural 2500
Interviewed 30
Sangli 2225
Total 1700
2.82 114/100 000 23.0
Urban 300
Rural 1400
Interviewed 31
TB – tuberculosis, PF – Plasmodium falciparum
Data analysis
Quantitative data from the survey were entered into a data mask using Epi Info v. 3.5.3 (CDC, Atlanta, 
GA, USA). The data were used to calculate the percentage availability of the study medicines in the pri-
vate retail pharmacy outlets, by districts, and by urban and rural areas. We recorded the different avail-
able formulations, products and brand names of the six selected essential medicines available in the pri-
vate retail pharmacies and the level of availability. The results from the pharmacy survey were compared 
to data on approved products available in these four pharmaceutical databases. There is no centralised 
database in India of available pharmaceutical brands. We collected data on the different brands of the 
tracer medicines available in the Indian market by consulting three open access Indian pharmaceutical 
databases: CIMS India, Medindia, and Medguide. These industry databases are primarily reference sourc-
es for doctors, patients and the general public; they are not regularly updated and therefore do not in-
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clude information on all available pharmaceutical brands in India. We also acquired data from Pharma-
trac, a commercial database of Indian national pharmaceutical sales run by the pharmaceutical market 
research company AIOCD Pharmasoftech AWACS Pvt. Ltd.
Research ethics
The research proposal was cleared by the Institutional Research Ethics Committee of the Foundation for 
Research in Community Health in Mumbai and by the ethical review procedures of the University of Ed-
inburgh’s School of Social and Political Science. Written permission to conduct research for this study was 
obtained from government health officials and medical officers including the Secretary of the Ministry of 
Health and Family Welfare (Maharashtra). All data were anonymised in a secure database.
RESULTS
The availability of the tracer medicines in the study pharmacies
Details concerning the availability of the six study medicines in the four districts are shown in Table 2. 
Of the 124 private retail pharmacies in the four districts, 63.7 percent (n = 79) were urban and 36.3 per-
cent (n = 45) were rural. As the Mumbai City District is entirely urban, the percentage of urban private 
retail pharmacies is high in the sample. The total availability in the retail pharmacies in the study districts 
of metformin was very high (91.9%) followed by rifampicin (64.5%). The availability of metformin was 
high in urban as well as rural areas. The availability of oxytocin (42.7%) and fluoxetine (41.1%) was mod-
erate; there was slightly less availability of artemisinin (33.1%). Lamivudine had the lowest availability 
(22.6%); it had very low availability in the rural areas (4.4%). Oxytocin was available in less than half the 
study pharmacies in the rural areas (46.7%), and had slightly lower availability in the urban areas (40.5%). 
In Dhule and Sangli districts, there was higher availability of artemisinin in the rural areas than in the ur-
ban areas, whereas in Nagpur higher levels of availability were found in the urban areas.
Table 2. The number and percentage of pharmacies where each tracer medicine was found in the four districts 
(January – May 2012)
meDicines
nAgpur Dhule sAngli mumbAi totAl
15 urbAn 15 rurAl 18 urbAn 15 rurAl 16 urbAn 15 rurAl 30 urbAn ru-
rAl
79 urbAn 45 rurAl 124 grAnD 
totAl
N % N % N % N N N % N % N % N % %
Metformin 15 100% 12 80% 16 88.9% 13 86.7% 15 93.8% 13 86.7% 30 100% NA 76 96.2% 38 84.4% 91.9%
Fluoxetine 9 60% 5 33.3% 4 22.2% 1 6.7% 8 50.0% 2 13.3% 22 73.3% NA 43 54.4% 8 17.8% 41.4%
Rifampicin 13 86.9% 9 60.0% 10 55.6% 5 33.3% 12 75.0% 6 40.0% 25 83.3% NA 60 75.9% 20 44.4% 64.5%
Lamivudine 5 33.3% 0 0 2 11.1% 1 6.7% 6 37.5% 1 6.7% 13 43.3% NA 26 32.9% 2 4.4% 22.6%
Artemisinin 9 60.0% 4 26.7% 7 38.9% 7 46.7% 3 18.8% 4 26.7% 7 23.3% NA 26 32.9% 15 33.3% 33.1%
Oxytocin 11 73.3% 6 40.0% 6 33.3% 6 40.0% 9 56.8% 9 60.0% 6 20.0% NA 32 40.5% 21 46.7% 42.7%
The availability of different products of the selected medicines
The top row of Table 3 shows the number of brands for each medicine recorded in the pharmacy survey. 
The next 4 rows give the number of available brands for each of the six tracer medicines listed in three 
open access databases (CIMS, Medindia, Medguide). Following this is the number of brands listed in 
Pharmatrac. As can be seen there is some divergence in the numbers of brands for each medicine listed 
in each database. The databases agreed on general levels of availability: the medicine with the highest 
number of brands was metformin, this was followed by artemisinin, then rifampicin; there were relative-
ly fewer brands of lamivudine and oxytocin. This pattern reflected the availability of brands in the phar-
macy survey.
In the databases and the pharmacy survey, with the exception of oxytocin, all the tracer medicines have 
a high number of FDC brands. The number for lamivudine was more than double its SDFs; for metformin 
it was almost three times the level. The Pharmatrac data on pharmaceutical sales showed that for each 
tracer medicine a number of brands had zero sales. Across the six medicine in their SDF and FDC forms, 
zero sales were recorded for 13% to 63% of the available brands in the single year examined (November 
2011 – October 2012). The study found that of the brands that were available in India according to the 
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four databases, only a small proportion were available in the study pharmacies. Metformin reported the 
highest number of products, followed by artemisinin, and then rifampicin.
The frequency of products of the selected medicines available in the study 
pharmacies
Data for the frequency of the availability of products of the six tracer medicines in the private retail phar-
macies is shown in Table 4. The survey found that only a small number of products had relatively high 
levels of availability across the study pharmacies. Table 4 shows the top 3 brands with the highest level 
of frequency for each medicine, based on the brands with a frequency above 3. For example, as we can 
see in Table 3 the two medicines with the largest number of brands in the survey are Metformin (74 
brands) and Artemesinin (27) brands, but the vast majority of those brands were available in the 3 or less 
of the study pharmacies.
Table 3. Number of brands in industry databases (2012) and numbers of brands found in pharmacies surveyed out 
in 2012
Drugs
oxytocin riFAmpicin Atemesinin lAmivuDine Fluoxetine metFormin
sDF FDc sDF FDc sDF FDc sDF FDc sDF FDc sDF FDc
Number of brands in pharmacy 
survey (January – May 2012)
6 0 6 17 14 13 5 4 11 3 25 59
Number of brands in CIMS (2012) 19 227 356 73 111 622
Number of Brands in Medindia 
(2012)
23 38 154 56 69 219
Number of brands in Medguide 
(2012)
25 528 500 101 243 1110
Total brands (excluding duplicates) 28 2 125 429 472 78 32 74 169 93 170 514
Number of brands in Pharmatrac 
database (Nov 2011 – Oct 2012)
18 0 22 236 188 68 9 45 80 34 123 536
Number brands in Pharmatrac with 
zero sales (Nov 2011 – Oct 2012)
6 0 14 92 61 9 4 8 32 18 29 108
SDF – single drug formulations, FDC – fixed dose combinations
Table 4. Brands with highest frequency of availability in study pharmacies (January – May 2012)
stuDy meDicine strength brAnD nAme Frequency
Artemisinin SDFs:
1. Arthether 150 mg AB-Ther 8
2. Artesunate 60 mg Falcigo 8
3. Arthemether 80 mg Larither 3
Larinate, Falcinil, Asunate, Amthar, Mdther, Nomart, Maligon-ART, 
Artither, Rapither AB, Match, Artifact
Less than 
3
Artemisinin FDCs:
1. Arthemether 80 mg, Lumfantrine 480 
mg
80 mg Lumerax 13
Combither, Combither forte, Rezatrin forte, Arte plus CD, Lumether 
forte, Lumate-AT, Lumeart, Larinate MF kit, Falcigo SP kit
1
Fluoxetine SDFs
1. Fluoxetine 20 mg Fludac 49
2. Fluoxetine 20 mg Flunil 23
Flutin, Prodac, Platin, Faxtin, Flunat, Flux, Fledore, Flugen, Prodep
3 or less 
than 3
Fluoxetine FDCs:
1. Fluoxetine 20 mg, Alprazolam 0.25 
mg
20 mg Fluwel 4
Durian, Oleanz plus 1
Lamivudine SDF:
1. Lamivudine 100 mg Lamivir HBV 2
2. Lamivudine 150 mg Lavir 2
Lamivir, Lamidac 1
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stuDy meDicine strength brAnD nAme Frequency
Lamivudine FDCs:
1. Lamivudine 150 mg, Stavudine 30 mg 150 mg Lamistar 2
2. Lamivudine 150 mg, Stavudine 30 mg 150 mg Duovir 2
3. Lamivudine 300 mg, Zidovidine 300 
mg, Efavirenz (kit)
300 mg Duovir-E 2
Lamivir S, Triomune 1
Oxytocin SDFs:
1. Oxytocin 5 IU Pitocin 53
2. Oxytocin 5 IU Gynotocin 7
3. Oxytocin 5 IU Syntocinone 5
Oxytocin, Evatocin, Nitocin
3 or less 
than 3
Rifampicin SDFs:
1. Rifampicin 450 mg R-Cin 72
2. Rifampicin 450 mg Macox 3
Rifalone, Rifaplus, Famcin, Rimactane 1
Rifampicin FDCs:
1. Rifampicin 450 mg, Isoniazid 300 mg 450 mg R-Cinex 48
2. Rifampicin 450 mg, Isoniazid 300 mg, 
Ethambutol 800 mg
450 mg AKT3 12
3. Rifampicin 450 mg, Isoniazid 300 mg, 
Ethambutol 800 mg, Pyrazinamide 750 
mg
450 mg AKT4 11
4. Rifampicin 450  mg, Isoniazid 300 mg 450 mg Rimactazid 11
Forecox, Rinizide, Akurit 3, Akurit, Montonex forte, AKT2, Monto 2, 
Macox plus, Monto 3, RHE-FD, Rifa I-6
3 or less 
than 3
Metformin SDF:
1. Metformin Glycomet + SR 81
2. Metformin Glyciphage 73
3. Metformin Gluformin 21
Gluconorm 20
Bigomet 7
Walaphage 5
Metlong, Okamet
3 or less 
than 3
Metformin FDC:
1. Metformin, Glipizide Glynase MF 28
2. Metformin 500 mg, Glimepiride 2 mg Glycomet GP2 24
3. Metformin 500 mg, Glimepiride 1 mg Glycomet GP1 22
Glyciphage G (all) 19
Gluconorm (all) 12
Gemer, Gluformin (all), Metaglez, Glykind M 4-9
Diabend M, Diabetrol, Duotrol SR, EXEED PG plus, Gemer 2, Gemer 
P, Glimet, Glimet DS, GLIMI DM PLUS, Glimid M, Glimiprex MF, 
Glimitide plus, Glimster M, Glimster N1, Glimster PM2, Glimy M, 
Glipizide M, Glizid M, Gluconorm GT, Gluconorm G, Gluconorm 
G1, Gluconorm G2, Gluconorm GP1, Gluconorm GP2, Gluconorm 
80, Gluconorm P, Gluconorm PG1, Gluconorm PG2, Gluformin G, 
Gluformin G1, Gluformin GP2, Gluformin MF, Glycheck M, 
Glycinorm M, Glyciphage P, Glyciphage G1, Glyciphage G2, 
Glyciphage GP, Glyciphage GP1, Glyciphage GP2, Glyciphage MF, 
Glyciphage MR, Glyciphage P1, Glyciphage P15, Glyciphage PG, 
Glyciphage PG1, Glyciphage PG2, Glycomet GP2 forte, Glycomet FP, 
Glycomet G1, Glycomet MF, Glyconorm G, Glyconorm M, 
Glycontrol MF, Glymester M, Glymester M1, Glymester M2, Glymet 
DS, Glymet MR, Glymi M2, Glymin, Glymy M, Glyred M, GMR M1, 
GMT SR, Metaglez, Metaglez forte, Nuzide M, Okamet M, Pioplus 2, 
Piopod MF, Pioz MF G, Pioz G2, Pioz MF, Tribet 1, Triglaz
3 or less 
than 3
SDF – single drug formulations, FDC – fixed dose combinations
PA
PE
RS
June 2018  •  Vol. 8 No. 1 •  010402 8 www.jogh.org •  doi: 10.7189/jogh.08.010402
Millard et al.
DISCUSSION
The aim of this study is to assess the availability of six essential medicines in private retail outlets in Ma-
harashtra state. The concept of essential medicines was developed to promote rational use, lower cost, 
and improve access. This study found that despite the multiple brands of selected medicines listed in 
professional and commercial databases only a small fraction was available in private pharmacies.
As Table 2 shows, of the six essential medicines surveyed in the 124 pharmacies only metformin had high 
availability, this was followed by rifampicin at 64.5%, the other medicines where available in less than 
half the pharmacies studied. Market competition has certainly led to the approval of a very large number 
of brands of the six study medicines. According to the data we gathered from the three professional da-
tabases, the six medicines are represented by 2186 approved products each with different brand names; 
the commercial database Pharmatrac included 1359 brands with 978 of them marketed in 2011-12. This 
has not led to high levels of availability in the study pharmacies. The results of this study confirm what 
the studies mentioned in the introduction found, that in India there remains inadequate access to essen-
tial medicines. The strength of this study is that to our knowledge it is the first study of essential medi-
cines in India which compares data on availability in pharmacies with data on pharmaceutical products 
found in commercial and professional databases.
There are three categories of medicine on the market in India. The vast majority of medicines are gener-
ics; these are either “branded medicines” or “branded generics”. In India “branded medicines” are gener-
ic drugs manufactured by multinational companies or Indian companies and marketed under their orig-
inal brand name; these are the most popular drugs in the market. “Branded generics” are bioequivalent 
to the original product but marketed under another brand name by the same company or any other com-
pany [32]. As can be seen from the results of this survey, generic drugs on the Indian market are available 
in single drug formulations (SDFs) and fixed dose combinations (FDCs). There is also a small number of 
patented specialised drugs on the market in India such as anti-cancer medicines which are imported from 
the US and Europe.
Medicine packages in India by law display both the non-proprietary scientific generic name, plus the 
brand name. However, as previously mentioned, in India medicines are generally marketed and prescribed 
by brand name, not the scientific generic name. For example, in India, metformin, which is the interna-
tionally recognised scientific generic name of the drug, is marketed in the form of different products each 
having specific brand names (74 of these are listed in Table 4). Each product is sold at the Maximum Re-
tail Price which is written on the package; this price is applicable throughout India and varies only slight-
ly according to state level taxation. Each product contains the same medicine, but there is a wide varia-
tion in prices between different products and thus cost-effectiveness is not assured.
The results of this survey found that only a few of the approved products listed in the databases were 
available in the study pharmacies. Furthermore, the frequency of the availability of brands in the study 
pharmacies showed that only a small number of products were dominating the market; most of the prod-
ucts reported in the survey had frequencies of 3 or less. The reason behind the market dominance of cer-
tain products is unknown and more work needs to be done to understand prescribing practices, drug 
promotional activities including kickbacks, pricing and consumer preferences. A limitation of this research 
was that as we did not collect data on prices we were not able to explore whether this was a factor in the 
decision to stock particular brands.
Sales figures show that a large proportion of the 2186 approved products of the six essential medi-
cine are available on the Indian market, but there remain questions about whether this level of mar-
ket competition leads to wider availability of appropriate medicines and their rational use. For in-
stance a large number of the approved products have zero sales and the reason for this remains 
unexplained. Across the six medicines in their SDF and FDC forms, zero sales were recorded for 13% 
to 63% of the available brands in the single year examined (November 2011 to October 2012). There 
are also questions concerning the safety and effectiveness of the numerous available FDC formula-
tions. In 2007, the Indian regulatory body the Central Drugs Standard Control Organization (CDS-
CO) banned 294 FDCs which had been approved by state authorities but had never received central 
authorisation; in 2012 a further 45 FDCs were withdrawn [33,34].
The results of the survey show that pharmacies stocked a limited number of brands with consider-
able variation within and between pharmacies in the brands stocked. There was very high availabil-
ity of metformin (91.9%) in all study districts and in both urban and rural areas. The national disease 
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control program for diabetes has not been rolled out in all Indian states. In Maharashtra the program 
is still in its early stages. Metformin is supposed to be available at primary health centres, but this 
was generally not the case during the period of our study; it was available only in a few public health 
facilities in Mumbai City District. Diabetes, as a lifelong chronic disorder, provides an assured mar-
ket for pharmaceutical companies. The high levels of availability in the private retail pharmacies in 
the four study districts may be accounted for by the poor availability of metformin in public health 
facilities and the low level of development of the national disease control program in Maharashtra. It 
may also be the case that metformin has been strategically marketed in the area taking advantage of 
the low level of public provision.
There was high availability of rifampicin (64.5%) in all study districts with higher availability in ur-
ban compared to rural areas. Although the well-established national disease control program for tu-
berculosis has achieved significant progress over the last decade (RNTCP Status report 2009), stud-
ies have reported that 50%-80% of TB patients in India take treatment from private health care 
facilities [35,36]. Additionally the consumption of first line anti tuberculosis drugs in the private sec-
tor market is very high (65%) compared to the use in public health facilities [37].
The study found moderate levels of availability of oxytocin (42.7%) in the study pharmacies, slightly 
more in the rural areas than in the urban ones. There is a well-developed maternal child health pro-
gram in India and through this oxytocin is widely available at primary public health facilities, but 
unqualified staff and poor management of stocks and inadequate storage conditions all contribute 
towards poor availability of oxytocin in public health facilities and this may account for its availabil-
ity in the private pharmacies [38-42]. Additionally there is evidence that its availability in private 
pharmacies has contributed to its misuse to induce or speed labours [38-41].
The study found moderate availability of fluoxetine (41.1%) in the study pharmacies in urban areas 
and poor levels in rural areas. The national disease control programs for depression and other men-
tal health disorders are not well developed in India. Fluoxetine is included in the Indian national 
EML but it has low levels of availability in public health facilities. In addition there is a general lack 
of qualified doctors for prescribing such medicines in primary health care facilities. The low levels 
of availability in the study pharmacies may also be accounted for by the fact that private sector health 
facilities for treating depression and other mental health disorders are concentrated at the district 
headquarters. Other new medicines in the selective serotonin reuptake inhibitors group are now also 
available in India; this could also be a factor contributing to the low availability of fluoxetine.
With the exception of the urban area of Nagpur, the study showed low availability of artemisinin 
(33.1%) in both urban and rural private outlets. The national disease control program for malaria is 
generally well developed in India. However, this was not the case in urban areas of Nagpur district, 
which would account for the relatively high levels of artemisinin found here in the study pharmacies.
Of all the tracer medicines, lamivudine had the lowest availability in the study pharmacies. The sit-
uation was worse in the rural areas where in both Sangli and Dhule only one of the 15 surveyed phar-
macies stocked it, and in Nagpur it was not available. The national disease control program for HIV/
AIDS in India is relatively new, but it is a high priority program with good levels of funding, and con-
sequently a strong well-staffed infrastructure is now in place. This has improved the availability of 
anti-retroviral medicines in secondary and tertiary public health facilities in India [43]. Lamivudine 
is an expensive lifelong treatment and as such the first recourse for people with HIV/AIDS in India 
is to use free anti-retroviral medicines provided by the national disease control program. This would 
account for the low availability of lamivudine in the study pharmacies. However, stigma associated 
with HIV/AIDS remains a problem in India, and this is a major reason why some patients still opt for 
treatment in private health facilities.
CONCLUSION
In conclusion, this survey shows that the large number of brands of the six study medicines registered in 
India, as documented by professional and commercial databases, has not translated into sufficient avail-
ability of these medicines in the study pharmacies. A solution would be to strengthen the national disease 
control programs for conditions associated with the six selected medicines, as they are the major source 
of free medicines for the large section of the population with limited financial means. In a few instances, 
this can be attributed to well-functioning public health programs that are a major source of free medicines 
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for the large section of the population with limited financial means. Further strengthening of the nation-
al disease control programs for conditions associated with the six selected medicines is necessary as the 
private sector provision does not sufficiently ensure availability and affordability of medicines.
The present market based system also leads to irrational medicine use. The widespread use of brand names 
for prescribing is a case in point. It is acknowledged by the Indian Medical Council that the common 
practice of prescribing medicines by brand names can lead to confusion. In January 2013 it therefore 
asked doctors to prescribe drugs by scientific generic names to ensure compliance to clause 1.5 of the 
Indian Medical Council (Professional Conduct, Etiquette and Ethics) 2002 Regulations, which contains 
the provision that every physician should, as far as possible, prescribe drugs with scientific generic names 
in order to achieve rational prescribing and use of drugs [44]. This would be in accordance with the 
WHO’s guidance on the use of international non-proprietary names for safe prescription and dispensing 
of medicines [45]. The issue of the irrational use of FDCs in India has been addressed by McGettigan et 
al. [33].
In India there is no central database of products approved for manufacture and marketing by State Li-
censing Authorities. Recently the union health ministry’s expert panel has been constituted in a massive 
exercise to examine and regularise the thousands of FDCs products (over 5000) permitted to manufac-
ture and sale in the country by states without due approval from the Drugs Controller General of India 
(Ramesh Shankar, June 2014). CDSCO needs to review the number of brands on the market, taking into 
consideration sales, availability, price and the grounds for approval. There is also an urgent need for a 
consumer friendly central database which will enable people to verify manufacturing approval, efficacy 
and compare prices.
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